These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20193963)

  • 1. Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors.
    Muranyi AL; Dedhar S; Hogge DE
    Leuk Res; 2010 Oct; 34(10):1358-65. PubMed ID: 20193963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.
    Muranyi AL; Dedhar S; Hogge DE
    Exp Hematol; 2009 Apr; 37(4):450-60. PubMed ID: 19302919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
    Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
    Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
    Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
    Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells.
    Arseni N; Ahmed F; Hiddemann W; Buske C; Feuring-Buske M
    Haematologica; 2005 Nov; 90(11):1577-8. PubMed ID: 16266907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
    O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
    Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells.
    Griessinger E; Imbert V; Lagadec P; Gonthier N; Dubreuil P; Romanelli A; Dreano M; Peyron JF
    Leukemia; 2007 May; 21(5):877-85. PubMed ID: 17330097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia.
    Eriksson A; Höglund M; Lindhagen E; Aleskog A; Hassan SB; Ekholm C; Fhölenhag K; Jensen AJ; Löthgren A; Scobie M; Larsson R; Parrow V
    Biochem Pharmacol; 2010 Nov; 80(10):1507-16. PubMed ID: 20705060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells.
    Griessinger E; Frelin C; Cuburu N; Imbert V; Dageville C; Hummelsberger M; Sirvent N; Dreano M; Peyron JF
    Leukemia; 2008 Jul; 22(7):1466-9. PubMed ID: 18239622
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective small molecule inhibitors of p110α and δ isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors.
    Xing Y; Gerhard B; Hogge DE
    Exp Hematol; 2012 Nov; 40(11):922-33. PubMed ID: 22828407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.
    Kasper S; Breitenbuecher F; Hoehn Y; Heidel F; Lipka DB; Markova B; Huber C; Kindler T; Fischer T
    Leuk Res; 2008 Nov; 32(11):1698-708. PubMed ID: 18556063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
    Zeng Z; Samudio IJ; Zhang W; Estrov Z; Pelicano H; Harris D; Frolova O; Hail N; Chen W; Kornblau SM; Huang P; Lu Y; Mills GB; Andreeff M; Konopleva M
    Cancer Res; 2006 Apr; 66(7):3737-46. PubMed ID: 16585200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 inhibitors in acute myeloid leukemia.
    el-Shami K; Stone RM; Smith BD
    Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
    Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells.
    Grafone T; Palmisano M; Nicci C; Martelli AM; Emanuela O; Storti S; Baccarani M; Martinelli G
    Hematol Oncol; 2008 Sep; 26(3):159-66. PubMed ID: 18383555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
    Ravandi F; Jilani I; Estey E; Kantarjian H; Dey A; Aguilar C; Jitkaroon C; Giles F; O'Brien S; Keating M; Albitar M
    Leuk Res; 2007 Jun; 31(6):791-7. PubMed ID: 17156841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
    Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
    Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.